Browse > Article
http://dx.doi.org/10.7314/APJCP.2014.15.9.4071

Lack of Association Between CYP1A1 Polymorphisms and Risk of Bladder Cancer: a Meta-analysis  

Lu, Yu (Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University)
Zhang, Xiao-Lian (Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University)
Xie, Li (Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University)
Li, Tai-Jie (Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University)
He, Yu (Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University)
Peng, Qi-Liu (Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University)
Deng, Yan (Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University)
Wang, Jian (Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University)
Qin, Xue (Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University)
Li, Shan (Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.15, no.9, 2014 , pp. 4071-4077 More about this Journal
Abstract
Background: The effects of CYP1A1 gene polymorphisms on the risk of bladder cancer (BC) remain controversial. We carried out a meta-analysis to clarify the role of CYP1A1 gene polymorphisms in BC. Material and Methods: A comprehensive literature search was conducted up to November 20, 2013. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to estimate the strength of the association. Meta-regression, subgroup analysis, sensitivity analysis and publication bias were also performed. Results: Eight studies involving 1,059 BC cases and 1,061 controls were included. The meta-analysis showed that there was no significant association between the two common mutations of CYP1A1 and BC risk. For the I1e462Val A/G polymorphism with GG vs. AA the OR was 1.47 (95 % CI= 0.70-3.07, P =0.308). For the MspI T/C polymorphism, though a slight trend was found this was not statistically nonsignificant (CC vs.TT, OR = 1.24, 95 % CI= 0.98-1.58, P =0.078). Subgroup analyses by ethnicity also found no obvious association between CYP1A1 and BC risk. Conclusion: The present meta-analysis suggests that CYP1A1 polymorphism is not associated with bladder cancer risk.
Keywords
Bladder cancer; CYP1A1; I1e462Val; mspI; polymorphisms; meta-analysis;
Citations & Related Records
Times Cited By KSCI : 6  (Citation Analysis)
연도 인용수 순위
1 Sergentanis TN, Economopoulos KP (2010). Four polymorphisms in cytochrome P450 1A1 (CYP1A1) gene and breast cancer risk: a meta-analysis. Breast Cancer Res Treat, 122, 459-69.   DOI
2 Wolf A, Kutz A, Plottner S, et al (2005). The effect of benzo (a)pyrene on porcine urinary bladder epithelial cells analyzed for the expression of selected genes and cellular toxicological endpoints. Toxicology, 207, 255-69.   DOI
3 Yang XQ, Xu C, Sun Y, et al (2013). Diabetes mellitus increases the risk of bladder cancer: an updated meta-analysis. Asian Pac J Cancer Prev, 14, 2583-9.   과학기술학회마을   DOI   ScienceOn
4 Zeegers MP, Tan FE, Dorant E, et al (2000). The impact of characteristics of cigarette smoking on urinary tract cancer risk: a meta-analysis of epidemiologic studies. Cancer, 89, 630-9.   DOI
5 Pollard C, Smith SC, Theodorescu D (2010). Molecular genesis of non-muscle-invasive urothelial carcinoma (NMIUC). Expert Rev Mol Med, 12, e10.   DOI   ScienceOn
6 Romkes M, White C, Johnson J, et al (1996). Expression of cytochrome P450 mRNA in human lung, head and neck tumours, and normal adjacent tissues. Proc Am Assoc Cancer Res, 37, 105.
7 Shakhssalim N, Hosseini SY, Basiri A, et al (2010). Prominent bladder cancer risk factors in Iran. Asian Pac J Cancer Prev, 11, 601-6.
8 Shimada T (2006). Xenobiotic-metabolizing enzymes involved in activation and detoxification of carcinogenic polycyclic aromatic hydrocarbons. Drug Metab Pharmacokinet, 21, 257-76.   DOI   ScienceOn
9 Srivastava DS, Mandhani A, Mittal RD (2008). Genetic polymorphisms of cytochrome P450 CYP1A1 (*2A) and microsomal epoxide hydrolase gene, interactions with tobacco-users, and susceptibility to bladder cancer: a study from North India. Arch Toxicol, 82, 633-9.   DOI
10 Thakkinstian A, McElduff P, D'Este C, et al (2005). A method for meta-analysis of molecular association studies. Stat Med, 24, 1291-306.   DOI   ScienceOn
11 Wahid M, Mahjabeen I, Baig RM, et al (2013). Expression of CYP1A1 and GSTP1 in human brain tumor tissues in Pakistan. Asian Pac J Cancer Prev, 14, 7187-91.   과학기술학회마을   DOI   ScienceOn
12 Li X, Cui WP, Bai SF (2007). Analysis of the polymorphism of CYP1A1-MSPI gene in patients with bladder cancer. China Prac Med, 2, 3-5.   DOI
13 Kellermann G, Shaw CRLuyten-Kellerman M (1973). Aryl hydrocarbon hydroxylase inducibility and bronchogenic carcinoma. N Engl J Med, 289, 934-7.   DOI   ScienceOn
14 Kogevinas M, t Mannetje A, Cordier S, et al (2003). Occupation and bladder cancer among men in Western Europe. Cancer Causes Control, 14, 907-14.   DOI
15 Li S, Peng Q, Chen Y, et al (2013). DNA repair gene XRCC1 polymorphisms, smoking, and bladder cancer risk: a meta-analysis. PLoS One, 8, e73448.   DOI
16 Lu Y, Peng Q, Zeng Z, et al (2013). CYP2D6 phenotypes and Parkinson's disease risk: A meta-analysis. J Neurol Sci, 336, 161-8.
17 Ozturk T, Kahraman OT, Toptas B, et al (2011). The effect of CYP1A1 and GSTM1 gene polymorphisms in bladder cancer development in a Turkish population. In Vivo, 25, 663-8.
18 Manuguerra M, Matullo G, Veglia F, et al (2007). Multi-factor dimensionality reduction applied to a large prospective investigation on gene-gene and gene-environment interactions. Carcinogenesis, 28, 414-22.
19 Mooney LA, Bell DA, Santella RM, et al (1997). Contribution of genetic and nutritional factors to DNA damage in heavy smokers. Carcinogenesis, 18, 503-9.   DOI   ScienceOn
20 Murray GI, Taylor VE, McKay JA, et al (1995). Expression of xenobiotic metabolizing enzymes in tumours of the urinary bladder. Int J Exp Pathol, 76, 271-6.
21 Peng Q, Mo C, Tang W, et al (2013). DNA repair gene XRCC3 polymorphisms and bladder cancer risk: a meta-analysis. Tumour Biol, 35, 1933-44.
22 Hayashi S, Watanabe J, Nakachi K, et al (1991). Genetic linkage of lung cancer-associated MspI polymorphisms with amino acid replacement in the heme binding region of the human cytochrome P450IA1 gene. J Biochem, 110, 407-11.   DOI
23 Giri SK, Yadav A, Kumar A, et al (2012). CYP1A1 gene polymorphisms: modulator of genetic damage in coal-tar workers. Asian Pac J Cancer Prev, 13, 3409-16.   과학기술학회마을   DOI   ScienceOn
24 Grando JP, Kuasne H, Losi-Guembarovski R, et al (2009). Association between polymorphisms in the biometabolism genes CYP1A1, GSTM1, GSTT1 and GSTP1 in bladder cancer. Clin Exp Med, 9, 21-8.   DOI   ScienceOn
25 Guengerich FP, Shimada T (1998). Activation of procarcinogens by human cytochrome P450 enzymes. Mutat Res, 400, 201-13.   DOI   ScienceOn
26 Jiang X, Castelao JE, Yuan JM, et al (2012). Cigarette smoking and subtypes of bladder cancer. Int J Cancer, 130, 896-901.   DOI
27 Hiyama T, Yoshihara M, Tanaka S, et al (2008). Genetic polymorphisms and head and neck cancer risk (Review). Int J Oncol, 32, 945-73.
28 Ismail SI, Soubani M, Nimri JM, et al (2013). Cancer incidence in Jordan from 1996 to 2009--a comprehensive study. Asian Pac J Cancer Prev, 14, 3527-34.   과학기술학회마을   DOI   ScienceOn
29 Ji YN, Wang Q, Suo LJ (2012). CYP1A1 Ile462Val polymorphism contributes to lung cancer susceptibility among lung squamous carcinoma and smokers: a meta-analysis. PLoS One, 7, e43397.   DOI
30 Karbakhsh M, Dabbagh N, Shabani A, et al (2013). Age at diagnosis in bladder cancer: does opium addiction play a role? Asian Pac J Cancer Prev, 14, 4723-5.   과학기술학회마을   DOI   ScienceOn
31 Kawajiri K, Eguchi H, Nakachi K, et al (1996). Association of CYP1A1 germ line polymorphisms with mutations of the p53 gene in lung cancer. Cancer Res, 56, 72-6.
32 Brockmoller J, Cascorbi I, Kerb R, et al (1996). Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk. Cancer Res, 56, 3915-25.
33 Boffetta P, Jourenkova N, Gustavsson P (1997). Cancer risk from occupational and environmental exposure to polycyclic aromatic hydrocarbons. Cancer Causes Control, 8, 444-72.   DOI   ScienceOn
34 Dai LP, Wang YP, Wu XB, et al (2009). Study on the association of cytochrome P450 polymorphisms and the risk of esophageal cancer: a meta-analysis. Zhonghua Liu Xing Bing Xue Za Zhi, 30, 1198-202 (in Chinese).
35 Bosetti C, Pira ELa Vecchia C (2005). Bladder cancer risk in painters: a review of the epidemiological evidence, 1989-2004. Cancer Causes Control, 16, 997-1008.   DOI   ScienceOn
36 Botelho MC, Machado J, Cda Costa JM (2010). Schistosoma haematobium and bladder cancer: what lies beneath? Virulence, 1, 84-7.   DOI   ScienceOn
37 Cascorbi I, Brockmoller J, Roots I (1996). A C4887A polymorphism in exon 7 of human CYP1A1: population frequency, mutation linkages, and impact on lung cancer susceptibility. Cancer Res, 56, 4965-9.
38 Dorrenhaus A, Muller TRoos PH (2007). Increased CYP1A1 expression in human exfoliated urothelial cells of cigarette smokers compared to non-smokers. Arch Toxicol, 81, 19-25.   DOI
39 Fontana L, Delort L, Joumard L, et al (2009). Genetic polymorphisms in CYP1A1, CYP1B1, COMT, GSTP1 and NAT2 genes and association with bladder cancer risk in a French cohort. Anticancer Res, 29, 1631-5.
40 Fu Jing CB-c (2013). Relationship between genetic polymorphisms of CYP1A1, NQO1, and EPHX1 and susceptibility to bladder cancer. Chin J Cancer Prev Treat, 20, 10-4.
41 Bartsch H, Nair U, Risch A, et al (2000). Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers. Cancer Epidemiol Biomarkers Prev, 9, 3-28.
42 Vineis P, Veglia F, Garte S, et al (2007). Genetic susceptibility according to three metabolic pathways in cancers of the lung and bladder and in myeloid leukemias in nonsmokers. Ann Oncol, 18, 1230-42.   DOI   ScienceOn
43 Berber U, Yilmaz I, Yilmaz O, et al (2013). CYP1A1 (Ile462Val), CYP1B1 (Ala119Ser and Val432Leu), GSTM1 (null), and GSTT1 (null) polymorphisms and bladder cancer risk in a Turkish population. Asian Pac J Cancer Prev, 14, 3925-9.   과학기술학회마을   DOI   ScienceOn
44 Luch A (2005). Nature and nurture - lessons from chemical carcinogenesis. Nat Rev Cancer, 5, 113-25.   DOI   ScienceOn